BPC November 11 update

Biotech Stock watch list for week of November 14 2016

Weekly watchlist

The U.S. election dominated biotech headlines sending stocks soaring as investors viewed Donald Trump’s victory as a positive for biotech. On each of the last three trading days we saw on average almost 10% of stocks tracked by BioPharmCatalyst rising by at least 10%.

Just seven weeks remain in the trading year, yet over 50 binary data events are still slated for release this quarter. Please find below ten such biotech catalysts to keep on your watch list.

Drug Stage Catalyst

EIGR
Lonafarnib - LOWR HDV – 2
Chronic hepatitis delta virus (HDV)

Phase 2 Phase 2 presentation at AASLD November 14, 2016.

MDCO
Inclisiran
Hypercholesterolemia

Phase 3 Phase 3 trial to be initiated mid-2017.

RTRX
Sparsentan
Focal segmental glomerulosclerosis (FSGS)

Phase 3 Phase 3 trial to be initiated 2H 2017.

CERC
CERC-301
Major depressive disorder (MDD)

Phase 2 Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.

ARDM
Pulmaquin - ORBIT-3 and ORBIT-4
Non-cystic fibrosis bronchiectasis (non-CF BE).

Phase 3 Phase 3 data released December 1, 2016. One of two trials met primary endpoint.

OPHT
Fovista
Wet age-related macular degeneration (Wet-AMD)

Phase 3 Phase 3 data released December 12, 2016 - primary endpoint not met.

DVAX
HEPLISAV-B
Hepatitis B

PDUFA CRL February 25, 2013 and November 14, 2016. New PDUFA date August 10, 2017

ANTH
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency

Phase 3 Top-line data released December 27, 2016 - missed primary endpoint.

SGYP
Plecanatide
Constipation-predominant irritable bowel syndrome (IBS-C)

Phase 3 Phase 3 data from first and second trials met primary endpoints - December 9 and 22, 2016. NDA filing due 1Q 2017.

GNMX
NFC-1 - SAGA
mGluR mutation positive ADHD

Phase 2/3 Phase 2/3 data released March 20, 2017 - primary endpoint not met.